Mast cell chymase reduces the toxicity of Gila monster venom, scorpion venom, and vasoactive intestinal polypeptide in mice

被引:116
作者
Akahoshi, Mitsuteru [1 ]
Song, Chang Ho [1 ,2 ]
Piliponsky, Adrian M. [1 ,3 ]
Metz, Martin [1 ,4 ]
Guzzetta, Andrew [1 ]
Abrink, Magnus [5 ]
Schlenner, Susan M. [6 ,7 ]
Feyerabend, Thorsten B. [6 ,8 ]
Rodewald, Hans-Reimer [6 ,8 ]
Pejler, Gunnar [9 ]
Tsai, Mindy [1 ]
Galli, Stephen J. [1 ,10 ]
机构
[1] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA
[2] Chonbuk Natl Univ, Sch Med, Dept Anat, Jeonju, South Korea
[3] Univ Washington, Dept Pediat, Ctr Immun & lmmunotherapies, Seattle Childrens Res Inst, Seattle, WA 98195 USA
[4] Charite, Dept Dermatol & Allergy, Allergie Ctr Charite, D-13353 Berlin, Germany
[5] Swedish Univ Agr Sci, Dept Biomed Sci & Vet Publ Hlth, Uppsala, Sweden
[6] Univ Ulm, Inst Immunol, Ulm, Germany
[7] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA
[8] German Canc Res Ctr, Div Cellular Immunol, Heidelberg, Germany
[9] Swedish Univ Agr Sci, Dept Anat Physiol & Biochem, Uppsala, Sweden
[10] Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA
基金
欧洲研究理事会;
关键词
CYCLASE ACTIVATING POLYPEPTIDE; COMMON STRIPED SCORPION; HELODERMA-SUSPECTUM; SNAKE-VENOM; BEE VENOM; BIOLOGICAL-PROPERTIES; HOST-DEFENSE; SUBSTANCE-P; PEPTIDE; MOUSE;
D O I
10.1172/JCI46139
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
100103 [病原生物学]; 100218 [急诊医学];
摘要
Mast cell degranulation is important in the pathogenesis of anaphylaxis and allergic disorders. Many animal venoms contain components that can induce mast cell degranulation, and this has been thought to contribute to the pathology and mortality caused by envenomation. However, we recently reported evidence that mast cells can enhance the resistance of mice to the venoms of certain snakes and that mouse mast cell-derived carboxypeptidase A3 (CPA3) can contribute to this effect. Here, we investigated whether mast cells can enhance resistance to the venom of the Gila monster, a toxic component of that venom (helodermin), and the structurally similar mammalian peptide, vasoactive intestinal polypeptide (VIP). Using 2 types of mast cell-deficient mice, as well as mice selectively lacking CPA3 activity or the chymase mouse mast cell protease-4 (MCPT4), we found that mast cells and MCPT4, which can degrade helodermin, can enhance host resistance to the toxicity of Gila monster venom. Mast cells and MCPT4 also can limit the toxicity associated with high concentrations of VIP and can reduce the morbidity and mortality induced by venoms from 2 species of scorpions. Our findings support the notion that mast cells can enhance innate defense by degradation of diverse animal toxins and that release of MCPT4, in addition to CPA3, can contribute to this mast cell function.
引用
收藏
页码:4180 / 4191
页数:12
相关论文
共 79 条
[1]
Mast cell-orchestrated immunity to pathogens [J].
Abraham, Soman N. ;
St John, Ashley L. .
NATURE REVIEWS IMMUNOLOGY, 2010, 10 (06) :440-452
[2]
Nucleoside composition of Heloderma venoms [J].
Aird, Steven D. .
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR BIOLOGY, 2008, 150 (02) :183-186
[3]
Amitai Y, 1998, Public Health Rev, V26, P257
[4]
The extended cleavage specificity of the rodent β-chymases rMCP-1 and mMCP-4 reveal major functional similarities to the human mast cell chymase [J].
Andersson, Mattias K. ;
Karlson, Ulrika ;
Hellman, Lars .
MOLECULAR IMMUNOLOGY, 2008, 45 (03) :766-775
[5]
Beck D.D., 2005, BIOL GILA MONSTERS B
[6]
Triage for Leiurus quinquestriatus scorpion envenomation in children -: is routine ICU hospitalization necessary [J].
Ben-Abraham, R ;
Eshel, G ;
Winkler, E ;
Weinbroum, AA ;
Barzilay, Z ;
Paret, G .
HUMAN & EXPERIMENTAL TOXICOLOGY, 2000, 19 (12) :663-666
[7]
Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data [J].
Bischoff, Stephan C. .
NATURE REVIEWS IMMUNOLOGY, 2007, 7 (02) :93-104
[8]
BOUABBOUD CF, 1988, WESTERN J MED, V148, P577
[9]
Predator-prey arms races [J].
Brodie, ED ;
Brodie, ED .
BIOSCIENCE, 1999, 49 (07) :557-568
[10]
CAUGHEY GH, 1988, J PHARMACOL EXP THER, V244, P133